Apellis Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-12-01

Reporting Person: Grossi Federico (CHIEF MEDICAL OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-01	Common Stock	S	600	$48.25	Disposed	33177	Direct

Footnotes

F1: This is a scheduled sale from 10B5-1 trading plan.

F2: Includes 302 shares from 10/30/2020 ESPP purchase.